Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 30;36(24):3830-3843.
doi: 10.1002/sim.7394. Epub 2017 Aug 7.

Estimation of smooth ROC curves for biomarkers with limits of detection

Affiliations

Estimation of smooth ROC curves for biomarkers with limits of detection

Leonidas E Bantis et al. Stat Med. .

Abstract

Protein biomarkers found in plasma are commonly used for cancer screening and early detection. Measurements obtained by such markers are often based on different assays that may not support detection of accurate measurements due to a limit of detection. The ROC curve is the most popular statistical tool for the evaluation of a continuous biomarker. However, in situations where limits of detection exist, the empirical ROC curve fails to provide a valid estimate for the whole spectrum of the false positive rate (FPR). Hence, crucial information regarding the performance of the marker in high sensitivity and/or high specificity values is not revealed. In this paper, we address this problem and propose methods for constructing ROC curve estimates for all possible FPR values. We explore flexible parametric methods, transformations to normality, and robust kernel-based and spline-based approaches. We evaluate our methods though simulations and illustrate them in colorectal and pancreatic cancer data.

Keywords: Box-Cox; ROC; biomarker; cancer; censoring; classification; early detection; generalized gamma; kernels; limit of detection; spline.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Simulated data set of two normal distributions generated to attain true AUC=0.8 and expected level of censoring 50% due to a lower LOD. Left panel: Box-Cox (BC) and kernel(BC) based ROCs along with the true and the naive empirical. Right panel: Generalized gamma (GG), kernel(GG), and spline based ROCs along with the true and the naive empirical.
Figure 2
Figure 2
Figure (2a): ROC curves for CEA that refers to colon cancer. AUCs for the Box-Cox, Kernel(BC), HCNS (spline) and naive empirical are 0.699, 0.686, 0.744 and 0.6566 respectively. Figure (2b): ROC curves for CA19-9 that refers to pancreatic cancer. AUCs for the Box-Cox, Kernel(BC), GG, kernel(GG), spline and naive empirical are 0.8577, 0.8474, 0.8657, 0.8569, 0.8627, 0.8428. The corresponding AUC for the empirical when using all available data is 0.8651. We note that even though it seems so, the GG based ROC estimate does not exhibit a step on the right panel. It simply has a very steep curvature close to TPR = 0.7.

Similar articles

Cited by

References

    1. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of Biomarker Development for Early Detection of Cancer. Journal of National Cancer Institute. 2001;93:1054–1061. - PubMed
    1. Taguchi A, Rho Jh, Yan Q, Zhang Y, Zhao Y, Xu H, Tripathi SC, Wang H, Brenner DE, Kucherlapati M, Kucherlapati R, Boutin AT, Wang AY, DePinho RA, Feng Z, Lampe PD, Hanash SM. MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas. Cancer Prevention Research. 2015 doi: 10.1158/1940-6207.CAPR-15-0077. - DOI - PMC - PubMed
    1. McLaughlin R, O'Hanlon D, Kerin M, Kenny P, Grimes H, Given HF. Are elevated Levels of the Tumour Marker CA19-9 of any clinical significance?-An evaluation. Clin Chem Lab Med. 1999;168(2):124–126. - PubMed
    1. Kim HR, Lee CH, Han SK, Shim YS, Yim JJ. Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med. 2009;47:750–754. - PubMed
    1. Kessler HH, Stelzl E, Daghofer E, Santner BI, Marth E, Lackner H, Stauber RE. Semiautomated Quantification of Hepatitis B Virus DNA in a Routine Dignaostic Laboratory. Clinical and Diagnostic Laboratory Immunology. 2000;7(5):853–855. - PMC - PubMed

LinkOut - more resources